Nasal Spray
Acadia Halts Development of Nasal Prader-Willi Drug After Phase 3 Failure
Acadia Pharmaceuticals; carbetocin; Prader-Willi syndrome; Phase 3 trial; COMPASS PWS study; clinical trial failure; nasal spray; hyperphagia
J&J’s Spravato Surpasses $1 Billion in Revenue for 2024
J&J, Spravato, revenue, 2024, depression treatment, nasal spray
FDA Approves ARS’s Epinephrine Nasal Spray for Emergency Allergic Reactions
FDA approval, epinephrine nasal spray, ARS Pharmaceuticals, anaphylaxis treatment, needle-free alternative, EpiPen
Orexo’s Opioid Overdose Nasal Spray Fails FDA Review for Second Time
Orexo, OX124, FDA, Nasal Spray, Opioid Overdose, Naloxone, Human Factors Study, Technical Data